VUNO’s First AI-based Prospective Study Results Published in Critical Care

SEOUL, South Korea, Sept. 18, 2023 /PRNewswire/ — VUNO Inc., South Korean medical AI company announced that its AI-based cardiac arrest risk management system, VUNO Med®-DeepCARS™, has proven its clinical validity for the first time through a prospective study utilizing Real World Data(RWD).

VUNO announced that the multicenter clinical study paper, which confirms the clinical validity of VUNO Med®-DeepCARS™ through its initial prospective research, has been published in “Critical Care,” a leading international journal in intensive care medicine.

VUNO Med®-DeepCARS™ is a medical AI device that analyzes four vital signs: respiratory rate, body temperature, blood pressure, and heart rate to predict cardiac arrest within 24 hours in general ward patients. It’s Korea’s first cardiac arrest prediction AI medical device and is recognized as a breakthrough device by the Korean Ministry of Food and Drug Safety(MFDS).

In the study published in Critical Care, the VUNO research team conducted a multicenter study using patient data from general wards at four tertiary medical institutions: Seoul National University Hospital, Bundang Seoul National University Hospital, Inha University Hospital, and Dong-A University Hospital, each with varying sizes, locations, and medical environments.

A total of 55,083 patients admitted to general wards in all participating institutions over three months, comparing the in-hospital cardiac arrest (IHCA) prediction accuracy, unexpected intensive care unit transfer (UIT) prediction accuracy, and false alarm rate of VUNO Med®-DeepCARS™ with existing high-risk patient prediction systems like NEWS (National Early Warning Score).

The study found that the predictive performance of VUNO Med®-DeepCARS™ had an AUROC score of 0.869, outperforming traditional methods (NEWS 0.767, MEWS 0.756). The number of alarms per 1,000 beds was more than halved compared to the same sensitivity level, proving higher trustworthiness in the alarms leading to actual medical interventions. Furthermore, its effectiveness was apparent across varying patient ages, genders, and times of occurrence.

In this study, VUNO Med®-DeepCARS™ displayed exceptional predictive abilities and adaptability in identifying high-risk patients, even in its first prospective research. It consistently performed at the same level as in previous retrospective studies published in renowned international journals.

Yeha Lee, CEO of VUNO said, “The significance of this research lies in its successful execution of the first multicenter prospective study with many variables and challenges, thereby reaffirming the consistent predictive performance and versatility of VUNO Med®-DeepCARS™” and he said, adding “We will continue to enhance the product’s credibility in clinical settings by conducting additional prospective research. We are committed to introducing it to more medical settings as essential care to ensure patient safety.”

 

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PR Newswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, PR Newswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.